SeleXel Overview

  • Founded
  • 2006
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

SeleXel General Information


Developer of biotech solutions intended to treat invasive or metastatic cancers. The company develops a portfolio of molecules based on the RNA interference technology that inhibit very specifically the production of a protein playing a key role in the development or progression of cancer, enabling healthcare professionals to restore the ability of the immune system to eliminate the tumor.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Primary Office
  • Centre Pierre Potier
  • 1 place Pierre Potier Oncopole input B
  • 31100 Toulouse
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SeleXel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Generating Revenue
To view SeleXel’s complete valuation and funding history, request access »

SeleXel Executive Team (3)

Name Title Board Seat Contact Info
Pierre Attali MD Co-Founder & President
Florence Cabon Co-Founder
To view SeleXel’s complete executive team members history, request access »

SeleXel Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Agoranov Accelerator/Incubator 000 0000 000000 0
To view SeleXel’s complete investors history, request access »